Stavudine sodium

Category	Human immunodeficiency Virus (HIV)
CAS	134624-73-0
Description	Stavudine sodium is a dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. Stavudine sodium is an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. Stavudine sodium triphosphate inhibits the HIV reverse transcriptase by competing with natural substrate, thymidine triphosphate. It also causes termination of DNA synthesis by incorporating into it. Mice were treated for 2 weeks with stavudine d4T (500 mg/kg/day), L-carnitine (200 mg/kg/day) or both drugs concomitantly. Body fatness was assessed by dual energy X-ray absorptiometry, and investigations were performed in plasma, liver, muscle and WAT. D4T reduced the gain of body adiposity, WAT leptin, whole body FAO and plasma ketone bodies, and increased liver triglycerides and plasma aminotransferases with mild ultrastructural abnormalities in hepatocytes.

Quotation Now

Product Information

Synonyms	Zerit sodium; d4T sodium
IUPAC Name	sodium;[(2S,5R)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-2,5-dihydrofuran-2-yl]methanolate
Molecular Weight	246.2
Molecular Formula	C10H11N2NaO4
Canonical SMILES	CC1=CN(C(=O)NC1=O)C2C=CC(O2)C[O-].[Na+]
InChI	InChI=1S/C10H11N2O4.Na/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8;/h2-4,7-8H,5H2,1H3,(H,11,14,15);/q-1;+1/t7-,8+;/m0./s1
InChIKey	NPETYOHVRRLVHG-KZYPOYLOSA-N
Purity	>98%
Solubility	In Vitro: 10 mM in DMSO
Appearance	Solid powder
Storage	Store at -20°C
In Vitro	Stavudine (d4T) sodium (50 μM) significantly reduces the expression of the NLRP3 inflammasome gene, IL-18 production and Aβ 42-stimulated cellular production of IL-1β in THP-1 derived macrophages Stavudine (d4T) sodium (50 μM) inhibits the assembly of the NLRP3 inflammasome complex and down-regulates the phagocytosis of Aβ 42 by macrophages Stavudine (d4T) sodium (10 μM, 7 or 14 days) significantly induced CEM cells Apoptosis, especially after 14 days, and increases hydrogen peroxide levels.
In Vivo	Mice were treated for 2 weeks with stavudine d4T (500 mg/kg/day), L-carnitine (200 mg/kg/day) or both drugs concomitantly. Body fatness was assessed by dual energy X-ray absorptiometry, and investigations were performed in plasma, liver, muscle and WAT. D4T reduced the gain of body adiposity, WAT leptin, whole body FAO and plasma ketone bodies, and increased liver triglycerides and plasma aminotransferases with mild ultrastructural abnormalities in hepatocytes .
Target	Reverse Transcriptase; HIV; Nucleoside Antimetabolite/Analog; NOD-like Receptor